Sun, Nov 29, 2015
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay Hedge Fund Index slips 0.29% in January; Healthcare & Biotechnology opens 2014 with 5.97% gain

Wednesday, February 19, 2014
Opalesque Industry Update - Hedge funds lost 0.29% in January, according to the Barclay Hedge Fund Index compiled by BarclayHedge. The Index gained 11.11% in 2013.

“After a rousing end to 2013, January bore witness to a complete reversal of key trends as investor sentiment turned defensive,” says Sol Waksman, founder and president of BarclayHedge.

“Global equity markets sold off as emerging markets came under renewed pressure from slowing in China, political unrest in Thailand and Turkey, and currency devaluation in Argentina." Overall performance by hedge fund sector was mixed in January. Twelve of Barclay’s 18 hedge fund indices had gains, while six indices had losses.

The Barclay Healthcare & Biotechnology Index jumped 5.97% in January, its largest one-month return since posting a gain of 6.27% in May of 2009.

“The Healthcare sector was a beneficiary of the move by investors out of cyclical stocks and into defensive stocks,” says Waksman.

The Barclay Equity Short Bias was up 1.95% in January, Distressed Securities gained 1.55%, European Equities were up 1.20%, Convertible Arbitrage gained 1.10%, and Fixed Income Arbitrage rose 0.94%.

In contrast, the Emerging Markets Index lost 2.47%, Pacific Rim Equities were down 0.96%, Equity Long Bias gave up 0.86%, anf Global Macro lost 0.55%.

The Barclay Fund of Funds Index was down 0.36% in January.


Press Release


What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Other Voices: Hedge fund marketing and the selling cycle[more]

    By Bruce Frumerman. How long is the selling cycle now? That’s a question my financial communications and sales marketing consulting firm has been asked on a regular basis by hedge fund firm owners and sales people, ever since we opened the doors to our firm in 1987 pre-crash. Wa

  2. People - Solus Alternative Asset Management adds chief strategist from BTIG[more]

    From Daniel Greenhaus joined hedge fund manager Solus Alternative Asset Management as managing director and chief strategist. He will work closely with Chris Bondy, Solus’ chief economist, managing director and executive vice president, said Chris Pucillo, CEO and chief investmen

  3. Opalesque Roundtable: Seeding deal terms can be onerous for hedge funds[more]

    Benedicte Gravrand, Opalesque Geneva for New Managers: Executives from fund of funds firms, family offices, a placement agent, a private equity firm, and an accounting firm gathered in Connecticut last month for the

  4. Opalesque Roundtable: Family offices flock to co-investment[more]

    Bailey McCann, Opalesque New York: Co-investments have been a hot topic for pension funds in recent years, as they try to move away from high fees and improve transparency. But now, family offices are more readily getting into the mix and establishing in-house deal teams, according to the delega

  5. More institutional investors invest in CTAs compared to last year despite dissatisfaction with performance[more]

    Benedicte Gravrand, Opalesque Geneva: "Despite a strong start to 2015 for CTAs in Q1, commodity market conditions have made return generation difficult for fund managers over much of the rest of the year to date," says Preqin’s November